

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Young *et al.* Application No. 09/996,265  
Patent No.: 6,855,493 Filed: November 28, 2001  
Issued: February 15, 2005 Group Art Unit: 1648  
For: METHODS OF ADMINISTERING/  
DOSING ANTI-RSV ANTIBODIES FOR  
PROPHYLAXIS AND TREATMENT Examiner: Stacy Brown CHEN  
Attorney Docket No: 10271-048-999  
(CAM #209073-999047)

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Enclosed herewith for appropriate action by the United States Patent and Trademark Office are the following documents:

1. Request for Certificate of Correction;
2. Certificate of Correction; and
3. Return Post Card.

The Commissioner is hereby authorized to charge the Certificate of Correction fee of \$100 to Jones Day Deposit Account No. 50-3013. The Commissioner is also authorized to charge any other fees necessary or credit any overpayment to Jones Day Deposit Account No. 50-3013.

Date: June 13, 2007

  
Fax: Anthony M. Insogna  
Tamera M. Pertmer, Ph.D. (Reg. No. 47,856)

For: Anthony M. Insogna (Reg. No. 35,203)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, NY 10017-6702  
(212) 326-3939

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee:	Young <i>et al.</i>	Application No.	09/996,265
Patent No.:	6,855,493	Filed:	November 28, 2001
Issued:	February 15, 2005	Group Art Unit:	1648
For:	METHODS OF ADMINISTERING/ DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT	Examiner:	Stacy Brown CHEN
		Attorney Docket No:	10271-048-999 (CAM #209073-999047)

**REQUEST FOR CERTIFICATE OF CORRECTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.322, the Patentees hereby request the issuance of a Certificate of Correction in connection with the above-identified patent. A Certificate of Correction setting forth the necessary corrections is submitted concurrently herewith.


An error in the paragraph spanning Cols. 95-96 is also being corrected to reflect that the framework sequences are those depicted in Figure 2 (not Figure 1). Support for this correction is found in the originally filed specification, *e.g.*, at page 69, lines 23-25, which corresponds to Col. 56, lines 28-31 of the issued patent. As such, Patentee submits that this correction does not constitute new matter and are fully supported by the specification of the originally filed application.

An error in the last full paragraph of column 37 is being corrected. Support for this correction is found, *e.g.*, in Figure 2, Table 2 and SEQ ID NOS: 7 and 8 (VH and VL domains of SYNAGIS); 226 and 227 (VH and VL chains of A4B4); 252 and 253 (VH and VL chains of A4B4(1)); 254 and 255 (VH and VL chains of A4B4L1FR-S28R); and 256 and 257 (VH and VL chains of A4B4 F52S). Similarly, an error in SEQ ID NO:11 is being corrected. As indicated in Table 2 of the specification, this sequence corresponds to the VL *domain* of A4B4L1FR-S28R. Specifically, SEQ ID NO:11 has been corrected to clarify that position 103 of the sequence is a *valine* (as opposed to a leucine). Patentee submits that support for this correction to the sequences is found in Table 2 of the specification and in the

Sequence Listing as originally filed. In particular, Table 2 indicates that the sequences corresponding to the VL *chain* for A4B4L1FR-S28R is SEQ ID NO:255. As noted above, Table 2 also indicates that the sequences of the corresponding VL *domain* for A4B4L1FR-S28R is SEQ ID NO:11. Since the VL *chain* of a particular antibody by definition includes the VL *domain* of that antibody, the sequences of the VL *chain* (SEQ ID NO: 255) necessarily contains a subsequence that is the sequence of the VL *domain* of SEQ ID NO:11. Patentee recently became aware of a discrepancy at amino acid position 103 between the VL chain sequence and its corresponding VL domain sequence. In the VL chain sequences, the amino acid at position 103 is a *valine*. However, the VL domain sequence incorrectly lists the amino acid at position 103 as a *leucine*. Accordingly, Patentee has corrected SEQ ID NO:11 of the VL *domain* to recite a *valine* at position 103 to correct this error and to correspond with *valine* correctly recited in the VL *chain* sequence (SEQ ID NO:255). Patentee submits that this correction does not introduce new matter because it is clear from Table 2 that SEQ ID NO:11 is the VL domain sequences of the antibody A4B4L1FR-S28R, and therefore it should be the same as the corresponding subsequence of the VL chain for this antibody (SEQ ID NO:255). The correct VL *domain* subsequence of the VL *chain* is found in the Sequence Listing as originally filed in SEQ ID NOS: 255. As such, Patentee submits that the corrections are fully supported by the specification of the originally filed application and do not constitute new matter.

Patentee authorizes the PTO to charge the estimated \$100 Certificate of Correction fee to Jones Day Deposit Account No. 50-3013. If there are any other fees due, please charge them to the same Deposit Account.

Date: June 13, 2007

  
For: Anthony M. Insogna  
Tamera M. Pertmer, Ph.D. (Reg. No. 47,856)

For: Anthony M. Insogna (Reg. No. 35,203)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, NY 10017-6702  
(212) 326-3939

Enclosure (Certificate of Correction)

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO. : 6,855,493  
 DATED : February 15, 2005  
 INVENTOR(S) : James F. Young  
 Scott Koenig  
 Leslie S. Johnson  
 William D. Huse  
 Jeffrey D. Watkins  
 Herren Wu

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 37, lines 37-38, change "with the exception that there is an amino acid substitution of an alanine for a valine at position 109." to --with the exception that there is a valine at position 103, numbered as shown in Figure 2A, and a glutamine at position 112, numbered as shown in Figure 2B.--.

Col. 95, line 49 – Col. 96, line 4, change "Fab fragments having the framework sequences of FIG. 1 and the indicated CDR sequences indicated listed in Table 2. SYNAGIS® AND AFFF are actual monoclonal antibodies with the framework sequences of FIG. 1 and constant regions as described in Johnson et al. (1997, Journal of Infectious Diseases 176:1215-1224) and U.S. Patent No. 5,824,307. The framework sequences of these antibodies may differ slightly from those of the Fab fragments." to --Fab fragments having the framework sequences of FIG. 2 and the CDR sequences listed in Table 2. SYNAGIS® is a monoclonal antibody with the framework sequences of Figure 1 and constant regions as described in Johnson et al. (1997, Journal of Infectious Diseases 176:1215-1224) and U.S. Patent No. 5,824,307. The framework sequences of this antibody may differ slightly from those of the Fab fragments.--.

Col. 125, SEQ ID NO:11 (amino acid 103), line 18, change "Leu" to --Val--.

MAILING ADDRESS OF SENDER:  
 JONES DAY  
 222 East 41st Street  
 New York, New York 10017  
 (212) 326-3939

PATENT NO. 6,855,493

No. of add'l. copies  
 @ 30¢ per page